Zentalis Pharmaceuticals, Inc.ZNTLNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P12
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -16.88% |
| Q2 2025 | 1.33% |
| Q1 2025 | -17.37% |
| Q4 2024 | -10.46% |
| Q3 2024 | -23.90% |
| Q2 2024 | -2.42% |
| Q1 2024 | -3.82% |
| Q4 2023 | 10.25% |
| Q3 2023 | 9.56% |
| Q2 2023 | -12.14% |
| Q1 2023 | 19.62% |
| Q4 2022 | -3.71% |
| Q3 2022 | -3.75% |
| Q2 2022 | -4.96% |
| Q1 2022 | 19.96% |
| Q4 2021 | -28.81% |
| Q3 2021 | 20.61% |
| Q2 2021 | 16.61% |
| Q1 2021 | 30.06% |
| Q4 2020 | 19.66% |
| Q3 2020 | 41.36% |
| Q2 2020 | 31.63% |
| Q1 2020 | 11.70% |
| Q4 2019 | 10.52% |
| Q3 2019 | 23.59% |
| Q2 2019 | 22.57% |
| Q1 2019 | 0.00% |